Good afternoon :)
Place Order
Add to Watchlist

Sun Pharma Advanced Research Co Ltd

SPARC

Sun Pharma Advanced Research Co Ltd

SPARC
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,960 cr, stock is ranked 689
High RiskStock is 3.41x as volatile as Nifty
206.373.79% (-8.12)
206.373.79% (-8.12)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,960 cr, stock is ranked 689
High RiskStock is 3.41x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,960 cr, stock is ranked 689
High RiskStock is 3.41x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-17.3156.26
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.650.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy).

Investor Presentation

View older 

Dec 19, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2023FY 2024TTM
Total Revenue249.66105.0272.48
Raw Materialssubtract0.000.00464.81
Power & Fuel Costsubtract5.756.14
Employee Costsubtract107.00141.84
Selling & Administrative Expensessubtract289.71267.06
Operating & Other expensessubtract50.3862.60
Depreciation/Amortizationsubtract11.7712.5112.53
Interest & Other Itemssubtract7.631.692.87
Taxes & Other Itemssubtract0.000.380.94
EPS-6.86-11.93-12.59
DPS0.000.000.00
Payout ratio0.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual report

PDF

Investor Presentation

Sep 4PDF
FY 2020

Annual report

PDF

Investor Presentation

Sep 19PDF
FY 2021

Annual report

PDF

Investor Presentation

Sep 10PDF
FY 2022

Annual report

PDF

Investor Presentation

Dec 28PDF
Dec 16PDF
Dec 9PDF
FY 2023

Annual report

PDF

Investor Presentation

Oct 28PDF
Oct 17PDF
Oct 13PDF
FY 2025

Annual Report Pending

Investor Presentation

Dec 19PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharma Advanced Research Co Ltd-18.2756.26
Sun Pharmaceutical Industries Ltd45.126.440.75%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd69.1016.690.83%

Price Comparison

Compare SPARC with any stock or ETF
Compare SPARC with any stock or ETF
SPARC
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding65.67%0.10%0.12%2.15%31.95%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep3.64%3.67%3.30%3.23%2.64%2.15%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Sun Pharma Advanced Research Co Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth

Growth
0.5214%0.72%0.72%41/51 (+2)
Nippon India Nifty Smallcap 250 Index Fund - Growth - Direct Plan

Growth
0.0316%0.11%-0.01%27/294 (-1)
SBI Nifty Smallcap 250 Index Fund - Direct Plan - Growth

Growth
0.0192%0.11%-0.01%148/294 (-9)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

SPARC has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Spotlight
Sun Pharma inks pact with UCSF and Tiller Therapeutics

The LoI outlines the key terms of license and rights for development and commercialization by Tiller. Under the LoI, SPARC will receive a 55% equity stake in Tiller upon execution of the agreement. The equity will vest in two tranches: 45% upon execution of the license agreement, and the remaining 10% upon the achievement of specific milestones or within 6 months of the agreement's execution. Anil Raghavan, CEO of SPARC, said, 'We are excited about the opportunity to partner with Tiller to advance potential treatment of solid tumors affecting millions each year, with no current cure.' Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The company reported a net loss of Rs 107.28 crore in Q2 FY25 as compared with net loss of Rs 86.08 crore in Q2 FY24. Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Shares of Sun Pharma Advanced Research Company fell 1.45% to Rs 227.15 on the BSE. Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Sun Pharma Advanced Research Company to acquire 55% stake in Tiller Therapeutics

Sun Pharma Advanced Research Company announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF), through the office of OTMA, and Tiller Therapeutics Inc. (Tiller) to license SPARC's rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller. Under the terms of the LOI, SPARC will receive 55% equity stake in Tiller upon execution of LOI. The equity will vest in two tranches; 45% equity will vest upon execution of license agreement and the remaining 10% equity will vest at the earlier of achievement of certain milestones by Tiller or within 6 months of execution of license agreement. Other terms of the license will be outlined in the license agreement. Powered by Capital Market - Live

5 days agoCapital Market - Live
Spotlight
Volumes spurt at Sun Pharma Advanced Research Company Ltd counter

Avanti Feeds Ltd, Jubilant Pharmova Ltd, Prestige Estates Projects Ltd, Oberoi Realty Ltd are among the other stocks to see a surge in volumes on NSE today, 16 December 2024.Sun Pharma Advanced Research Company Ltd notched up volume of 152.55 lakh shares by 14:14 IST on NSE, a 41.98 fold spurt over two-week average daily volume of 3.63 lakh shares. The stock rose 12.43% to Rs.238.31. Volumes stood at 2.85 lakh shares in the last session.Avanti Feeds Ltd saw volume of 41.59 lakh shares by 14:14 IST on NSE, a 13.45 fold spurt over two-week average daily volume of 3.09 lakh shares. The stock increased 7.45% to Rs.665.95. Volumes stood at 2.33 lakh shares in the last session.Jubilant Pharmova Ltd notched up volume of 10 lakh shares by 14:14 IST on NSE, a 6.16 fold spurt over two-week average daily volume of 1.62 lakh shares. The stock slipped 1.86% to Rs.1,093.60. Volumes stood at 1.3 lakh shares in the last session.Prestige Estates Projects Ltd recorded volume of 18.13 lakh shares by 14:14 IST on NSE, a 3.69 times surge over two-week average daily volume of 4.91 lakh shares. The stock gained 4.47% to Rs.1,833.00. Volumes stood at 7.81 lakh shares in the last session.Oberoi Realty Ltd clocked volume of 30.79 lakh shares by 14:14 IST on NSE, a 3.26 times surge over two-week average daily volume of 9.43 lakh shares. The stock gained 6.90% to Rs.2,263.75. Volumes stood at 6.57 lakh shares in the last session.Powered by Capital Market - Live

6 days agoCapital Market - Live
Spotlight
Sun Pharma Advanced Research Company Ltd leads gainers in 'A' group

Jindal Worldwide Ltd, Vakrangee Ltd, Wockhardt Ltd and Hemisphere Properties India Ltd are among the other gainers in the BSE's 'A' group today, 16 December 2024.Sun Pharma Advanced Research Company Ltd spiked 9.83% to Rs 232.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 3.07 lakh shares were traded on the counter so far as against the average daily volumes of 42206 shares in the past one month. Jindal Worldwide Ltd surged 8.71% to Rs 419.9. The stock was the second biggest gainer in 'A' group. On the BSE, 49383 shares were traded on the counter so far as against the average daily volumes of 42696 shares in the past one month. Vakrangee Ltd soared 8.53% to Rs 30.14. The stock was the third biggest gainer in 'A' group. On the BSE, 21.87 lakh shares were traded on the counter so far as against the average daily volumes of 13.16 lakh shares in the past one month. Wockhardt Ltd rose 7.59% to Rs 1502.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.28 lakh shares were traded on the counter so far as against the average daily volumes of 47546 shares in the past one month. Hemisphere Properties India Ltd exploded 7.40% to Rs 183.5. The stock was the fifth biggest gainer in 'A' group. On the BSE, 64624 shares were traded on the counter so far as against the average daily volumes of 46248 shares in the past one month. Powered by Capital Market - Live

6 days agoCapital Market - Live
Spotlight
Volumes jump at Sun Pharma Advanced Research Company Ltd counter

Raymond Ltd, Praj Industries Ltd, Adani Green Energy Ltd, Mangalore Refinery And Petrochemicals Ltd are among the other stocks to see a surge in volumes on NSE today, 22 November 2024.Sun Pharma Advanced Research Company Ltd witnessed volume of 40.83 lakh shares by 14:14 IST on NSE, a 13.33 times surge over two-week average daily volume of 3.06 lakh shares. The stock increased 8.35% to Rs.206.23. Volumes stood at 2.59 lakh shares in the last session.Raymond Ltd recorded volume of 17.78 lakh shares by 14:14 IST on NSE, a 12.91 times surge over two-week average daily volume of 1.38 lakh shares. The stock gained 8.45% to Rs.1,547.45. Volumes stood at 1.68 lakh shares in the last session.Praj Industries Ltd notched up volume of 51.83 lakh shares by 14:14 IST on NSE, a 12.5 fold spurt over two-week average daily volume of 4.15 lakh shares. The stock rose 9.73% to Rs.741.20. Volumes stood at 3.12 lakh shares in the last session.Adani Green Energy Ltd saw volume of 168.43 lakh shares by 14:14 IST on NSE, a 8.88 fold spurt over two-week average daily volume of 18.97 lakh shares. The stock dropped 4.30% to Rs.1,096.40. Volumes stood at 95.24 lakh shares in the last session.Mangalore Refinery And Petrochemicals Ltd notched up volume of 202.28 lakh shares by 14:14 IST on NSE, a 8.26 fold spurt over two-week average daily volume of 24.50 lakh shares. The stock rose 6.57% to Rs.154.58. Volumes stood at 14.9 lakh shares in the last session.Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Spotlight
SPARC drops as Q2 net loss widens to Rs 107 crore

Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Total expenses rose 3.43% YoY to Rs 120.07 crore in September 2024 quarter. Employee benefit expenses was Rs 38.48 crore (up 25.3% YoY), professional charges stood at Rs 30.75 crore (down 26.58% YoY), clinical trial expenses at Rs 25.53 crore (up 40.2% YoY). Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 107.33 crore in the September 2024 quarter

Net Loss of Sun Pharma Advanced Research Company reported to Rs 107.33 crore in the quarter ended September 2024 as against net loss of Rs 86.42 crore during the previous quarter ended September 2023. Sales declined 39.28% to Rs 12.86 crore in the quarter ended September 2024 as against Rs 21.18 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.8621.18 -39 OPM %-800.23-431.87 - PBDT-104.01-83.24 -25 PBT-107.17-86.42 -24 NP-107.33-86.42 -24 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sun Pharma Advanced Research Company to convene board meeting

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 4 November 2024Powered by Capital Market - Live

1 month agoCapital Market - Live

Sun Pharma Advanced Research Company reports consolidated net loss of Rs 95.90 crore in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 95.90 crore in the June 2024 quarter

Net Loss of Sun Pharma Advanced Research Company reported to Rs 95.90 crore in the quarter ended June 2024 as against net loss of Rs 95.35 crore during the previous quarter ended June 2023. Sales declined 29.81% to Rs 16.81 crore in the quarter ended June 2024 as against Rs 23.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.8123.95 -30 OPM %-555.38-426.64 - PBDT-92.36-92.25 0 PBT-95.50-95.35 0 NP-95.90-95.35 -1 Powered by Capital Market - Live

4 months agoCapital Market - Live